Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Special Report
What ACCC wants from Medicines Australia
The ACCC may have approved MA's new Code of Conduct in its draft determination handed down on Friday but its changes to the proposed transparency regime have already been identified by the industry association as possible deal breakers.
Open Forum
Generic myths: a pharmacist view
In the public mind, generic medicines continue to battle the idea that they are somehow inferior to original brands, but the pharmacy is not the same as the supermarket says Professor Andrew McLachlan.
Pipeline Monitor
Amgen boosts Humira biosimilar
It's been a big week on the global stage for Amgen, which reported encouraging results from trialling a biosimilar of AbbVie's Humira and won early FDA filing acceptance for a new leukaemia treatment.
Working Life
Reps say manager's style is key to retention
Some 83 per cent of Australian pharma sales reps have considered leaving their jobs, often due to what they regard as poor management says a survey presented at last week's Eyeforpharma sales and marketing conference.
Approvals Action
Competition for PAH treatment
The TGA has approved a generic competitor for bioCSL's PAH treatment Flolan Kit while the Alcon division of Novartis has won approval of a first-time treatment for vitreomacular traction.